Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12926843 | 1.00 | TSHR (0.35) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL2396260 | 1.00 | TSHR (0.35) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL899202 | 0.97 | TSHR (0.40) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL5283805 | 0.97 | TSHR (0.40) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL5289489 | 0.97 | TSHR (0.40) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL899174 | 0.97 | TSHR (0.40) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL897998 | 0.97 | TSHR (0.40) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL899043 | 0.97 | TSHR (0.40) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL5287059 | 0.97 | TSHR (0.40) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL5286905 | 0.97 | TSHR (0.40) | TSHRTHRBGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947854-B2 | Phospholipase inhibitor; prevention or therapy of microbial infection; bactericides; fungicides; viricides; parasiticides; using quaternary or phosphonium group containing compounds | THE UNIVERSITY OF SYDNEY (AU) | 2011-05-24 | — | — | US | claimed |
| US-20080275003-A1 | Bis-Cationic Compounds and Use Thereof | THE UNIVERSITY OF SYDNEY (AU) | 2008-11-06 | — | — | US | claimed |
| EP-1689698-A4 | BIS-CATIONIC COMPOUNDS AND USE THEREOF | UNIV SYDNEY (AU) | 2007-09-05 | — | — | EP | claimed |
| JP-2007510672-A | — | — | 2007-04-26 | — | — | JP | claimed |
| EP-1689698-A1 | BIS-CATIONIC COMPOUNDS AND USE THEREOF | THE UNIVERSITY OF SYDNEY (AU) | 2006-08-16 | — | — | EP | claimed |
| WO-2005047230-A1 | BIS-CATIONIC COMPOUNDS AND USE THEREOF | THE UNIVERSITY OF SYDNEY (AU) | 2005-05-26 | — | — | WO | claimed |
| US-7947854-B2 | Phospholipase inhibitor; prevention or therapy of microbial infection; bactericides; fungicides; viricides; parasiticides; using quaternary or phosphonium group containing compounds | THE UNIVERSITY OF SYDNEY (AU) | 2011-05-24 | — | — | US | disclosed |
| US-7947854-B2 | Phospholipase inhibitor; prevention or therapy of microbial infection; bactericides; fungicides; viricides; parasiticides; using quaternary or phosphonium group containing compounds | THE UNIVERSITY OF SYDNEY (AU) | 2011-05-24 | — | — | US | disclosed |
| US-7947854-B2 | Phospholipase inhibitor; prevention or therapy of microbial infection; bactericides; fungicides; viricides; parasiticides; using quaternary or phosphonium group containing compounds | THE UNIVERSITY OF SYDNEY (AU) | 2011-05-24 | — | — | US | disclosed |
| US-20080275003-A1 | Bis-Cationic Compounds and Use Thereof | THE UNIVERSITY OF SYDNEY (AU) | 2008-11-06 | — | — | US | disclosed |
| US-20080275003-A1 | Bis-Cationic Compounds and Use Thereof | THE UNIVERSITY OF SYDNEY (AU) | 2008-11-06 | — | — | US | disclosed |
| US-20080275003-A1 | Bis-Cationic Compounds and Use Thereof | THE UNIVERSITY OF SYDNEY (AU) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275003-A1 | Bis-Cationic Compounds and Use Thereof | PLCB1, PLCB3, PLA2G4B | TSHR 4481/4885THRB 1791/4885GNAI3 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.